Vantage logo

Lilly spends big on mirikizumab

With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.

Vantage logo

First blood: Rubius approaches its big test

The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…